PARKINSON KASALLIGI, DOPAMIN YETISHMOVCHILIGI VA SIMPTOMATIK DAVOLASH
Keywords:
Parkinson kasalligi, dopamin yetishmovchiligi, levodopa, dopamin agonistlari, simptomatik davolash, neyrodegeneratsiya, harakat buzilishlari, MAO-B inkibatorlari, COMT inkibatorlarilari, hayot sifatiAbstract
Ushbu ilmiy ishda Parkinson kasalligining asosiy patofiziologik sababi bo‘lgan dopamin yetishmovchiligi va unga bog‘liq simptomlar tahlil qilingan. Parkinson — markaziy asab tizimining surunkali-degenerativ kasalligi bo‘lib, nigrostrial yo‘llarda dopamin miqdorining kamayishi natijasida harakat buzilishlari yuzaga keladi. Bemorlarda tremor, bradikineziya, mushaklar rigidligi va muvozanat buzilishlari kuzatiladi. Mazkur ishda simptomatik davolash usullari, jumladan, levodopa, dopamin agonistlari, MAO-B inkibatorlari va boshqa dori vositalarining samaradorligi yoritilgan. Shuningdek, dori vositalarining nojo‘ya ta’sirlari va bemorning hayot sifatiga ko‘rsatadigan ta’siri haqida ham to‘xtalib o‘tilgan. Ishning maqsadi — Parkinson kasalligining zamonaviy simptomatik davolash yondashuvlarini tahlil qilish va dopamin yetishmovchiligini bartaraf etishga qaratilgan muolajalarni o‘rganishdan iborat.
Downloads
References
Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. The Lancet, 386(9996), 896–912.
Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, 79(4), 368–376.
Wise, R. A. (2004). Dopamine, learning and motivation. Nature Reviews Neuroscience, 5(6), 483–494.
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988). Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. New England Journal of Medicine, 318(14), 876–880.
Olanow, C. W., Stern, M. B., & Sethi, K. (2009). The scientific and clinical basis for the treatment of Parkinson disease. Neurology, 72(21 Suppl 4), S1–S136.
Rascol O. et al., The Lancet, 2000
Goodwin VA, et al. (2008). Effectiveness of exercise in Parkinson's disease: a meta-analysis. Movement Disorders, 23(5), 631–640.
Kalia LV, Lang AE, 2015.
Dauer W, Przedborski S, 2003.
Dorsey ER, et al. (2018). Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis. Lancet Neurology.
Ferreira JJ, Lees A, et al. (2016). Opicapone as adjunct to levodopa therapy in Parkinson’s disease: a randomized, controlled trial. Lancet Neurology.
Schrag A, Jahanshahi M, Quinn N. (2000). How does Parkinson's disease affect quality of life? J Neurol Neurosurg Psychiatry.
